Page 5 - Mass Ave Global News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Mass ave global. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Mass Ave Global Today - Breaking & Trending Today

Zhaoke Ophthalmology Limited (6622.HK) Announces Proposed Listing on the Main Board of SEHK_Final


 
Zhaoke Ophthalmology is an ophthalmic pharmaceutical company dedicated to the research, development and commercialization of therapies that address significant unmet medical needs in China. Leveraging its deep domain expertise while designing the pipeline, the Company has initially placed strategic emphasis on five major ophthalmic indications in China in terms of market potential, including dry eye disease, or DED, wet age-related macular degeneration, or wAMD, diabetic macular edema, or DME, myopia and glaucoma. Up to now, the Company has built a comprehensive ophthalmic drug pipeline of 25 candidates that covers most major ocular indications affecting the front and the back of the eye, through either in-house development or in-licensing. ....

United States , Hong Kong , Li Xiaoyi , Goldman Sachs Asia , Matthews International Capital Management , Golden Valley Global , Jefferies Hong Kong , International Placing , Zhaoke Ophthalmology , Orbimed Genesis Master Fund , Orbimed Partners Master Fund , Zhaoke Investment Fund , Hong Kong Zhaoke Ophthalmology Limited , Caas Capital Master Fund , Company Nansha , Jennison Associates , Stock Exchange Of Hong Kong Limited , Mass Ave Global Inc , Zhaoke Ophthalmology Limited , Launches Its , Fuel Its Future , Main Board , Stock Exchange , Hong Kong Limited , Jefferies Hong Kong Limited , Joint Sponsors ,

TodayIR: Zhaoke Ophthalmology Limited (6622.HK) Announces Proposed Listing on the Main Board of SEHK_Final


TodayIR: Zhaoke Ophthalmology Limited (6622.HK) Announces Proposed Listing on the Main Board of SEHK Final
DJ EQS-News: Zhaoke Ophthalmology Limited (6622.HK) Announces Proposed Listing on the Main Board of SEHK Final EQS-News / 16/04/2021 / 11:26 UTC+8 Zhaoke Ophthalmology Limited (6622.HK) Launches Its HKPO with 8 Cornerstone Investors to Fuel Its Future Growth
(April 16, 2021, Hong Kong) Zhaoke Ophthalmology Limited ( Zhaoke Ophthalmology or the Company ; stock code: 6622), an ophthalmic pharmaceutical company dedicated to the research, development and commercialization of therapies that address significant unmet medical needs, announced the proposed listing of its shares on the Main Board of The Stock Exchange of Hong Kong Limited ( SEHK ) today. Goldman Sachs (Asia) L.L.C., and Jefferies Hong Kong Limited are the Joint Sponsors, Joint Representatives, Joint Global Coordinators, Joint Bookrunners and Joint Lead Managers. ....

United States , Hong Kong , Li Xiaoyi , Kostenloser Wertpapierhandel , Goldman Sachs Asia , Matthews International Capital Management , Golden Valley Global , Jefferies Hong Kong , International Placing , Zhaoke Ophthalmology , Zhaoke Investment Fund , Hong Kong Zhaoke Ophthalmology Limited , Company Nansha , Jennison Associates , Marketing Press , Orbimed Genesis Master Fund , Orbimed Partners Master Fund , Caas Capital Master Fund , Stock Exchange Of Hong Kong Limited , Mass Ave Global Inc , Zhaoke Ophthalmology Limited , Announces Proposed Listing , Main Board , Ophthalmology Limited , Launches Its , Fuel Its Future Growth ,

Hive Ventures invests in InfuseAI and 15 more deal updates from Greater China


Hive Ventures invests in InfuseAI and 15 more deal updates from Greater China
April 6, 2021
Taiwanese machine learning startup InfuseAI has secured a $4.3 million Series A round funding led by the iPhone manufacturer Wistron Corporation, per a company statement on Tuesday. 
Taiwan-based, tech-driven global VC Hive Ventures partnering Taiwan Venture Capital Group and Silicon Valley Taiwan Investment also joined the current round.
InfuseAI is gearing up to foray into the Japan market, followed by Southeast Asia. 
InfuseAI, set up in 2018, offers a gamut of development and data analysis services to enterprises in fintech and manufacturing sectors. Now its flagship solution, PrimeHub is an all-in-one, on-premise machine learning (ML) platform that can help companies maximise machine learning operations (MLOps).   ....

T Ai Pei , Lehigh Hongking , Ryan Lee , Innolake Biopharm , Gezhi Industrial Development , Wistron Corporation , Huayu Technology Innovation , Jw Fund Management , Tripod Technology , Innovation Technology , Nantong Beixin New Energy Technology , Taiwan Venture Capital Group , Jiangsu Yueda Jintai Fund Management , Development Fund , Silicon Valley Taiwan Investment , Hive Ventures , Greater China , Capital China , Tiger Global Management , General Atlantic , Ocean Link , Capital Today , Hony Capital , Fund Management , Mass Ave Global , Cygnus Equity ,